BioSpace News Archive

Company’s Annual Contributions to American Epilepsy Society Have Totaled More Than $275,000

Additional Analysis in Phase 2 Trial of ADCETRIS plus OPDIVO in Patients with Frontline Hodgkin Lymphoma Aged 60 Years and Older

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Baxter International Inc. between February 21, 2019 and October 23, 2019, inclusive of the important January 24, 2020 lead plaintiff deadline in the case.

100% of evaluable patients in target dose had no relapse during the four-week follow-up period

Clinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa [07-December-2019] HORSHAM, Pa. , Dec. 7, 2019 /PRNewswire/ -- Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen

New results from the Phase 2 CAPTIVATE clinical trial show the potential of this fixed-duration, combination therapy for CLL patients starting treatment for the first time

Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24 months

Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health

Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy